Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 100 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, docetaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Durvalumab, Sirolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Terminated Phase 2 Interventional Results available

Neoadjuvant Immunotherapy in Brain Metastases

NCT04434560
Conditions
Brain Metastases, Adult
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Sarah Sammons, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Lung Cancer, Non-Small Cell
Interventions
Immunotherapeutic GSK2302032A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Newark, Delaware • Boston, Massachusetts • Rochester, Minnesota + 4 more
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri + 2 more
Conditions
Resectable Lung Non-Small Cell Carcinoma
Interventions
Biospecimen Collection, Proton Beam Radiation Therapy, Radiology, Treatment Planning
Procedure · Radiation · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
52
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 42 more
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Computed Tomography, Docetaxel, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Pemetrexed Disodium, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer
Interventions
cisplatin, pemetrexed disodium, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Lung Cancer
Interventions
conventional surgery, radiofrequency ablation
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer
Interventions
cisplatin, vinblastine sulfate, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
Center for Molecular Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Garden City, New York
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Carboplatin, Paclitaxel, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Edmonds, Washington
Conditions
Resectable, Early-stage, NSCLC
Interventions
Durvalumab, Oleclumab, Monalizumab, Danvatirsen
Drug · Combination Product
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 102 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
La Jolla, California • Fort Myers, Florida • Leesburg, Florida + 7 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non Small Cell Lung Cancer
Interventions
Velcade and Vorinostat
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
7
States / cities
Birmingham, Alabama • Stuart, Florida • Louisville, Kentucky + 3 more
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pemetrexed, Positron Emission Tomography, Zipalertinib
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Stanford, California + 2 more
Conditions
Non-small Cell Lung Cancer
Interventions
Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
29
States / cities
Fresno, California • Glendale, California • Orange, California + 23 more
Conditions
Non Small Cell Lung Cancer, NSCLC
Interventions
Cemiplimab, Platinum-based chemotherapy, Marlotamig, REGN10597
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
12
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 8 more
Completed Not applicable Interventional Results available

Study of Tarceva and Targretin in Stage I-II Lung Cancer

NCT00125372
Conditions
Carcinoma, Non-small-cell Lung
Interventions
erlotinib (Tarceva) and bexarotene (Targretin)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Lung Cancer (NSCLC)
Interventions
Cemiplimab, Adjuvant chemotherapy
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Detroit, Michigan